Compare Stocks: KYTX, ZBIO, NBTX, and STOK

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KYTX Kyverna Therapeutics	$8.13 -8.3%	$8.14	$3.27 ▼ $13.67	$502.76M	1.93	930,262 shs	953,704 shs
NBTX Nanobiotix	$43.68 -3.8%	$38.31	$8.03 ▼ $57.14	$2.21B	0.78	80,139 shs	119,709 shs
STOK Stoke Therapeutics	$31.40 -4.9%	$30.90	$18.00 ▼ $40.22	$2.03B	1.2	753,635 shs	1.10 million shs
ZBIO Zenas BioPharma	$31.62 +1.2%	$27.74	$13.50 ▼ $44.60	$2.06B	-1.03	846,710 shs	1.17 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KYTX Kyverna Therapeutics	+4.35%	+10.19%	+22.51%	-0.34%	+168.79%
NBTX Nanobiotix	+10.49%	+15.09%	+27.04%	+12.97%	+404.33%
STOK Stoke Therapeutics	+2.77%	+0.18%	+19.33%	+11.32%	+78.64%
ZBIO Zenas BioPharma	-2.07%	-0.13%	+1.79%	+57.51%	+97.16%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KYTX Kyverna Therapeutics	$8.13 -8.3%	$8.14	$3.27 ▼ $13.67	$502.76M	1.93	930,262 shs	953,704 shs
NBTX Nanobiotix	$43.68 -3.8%	$38.31	$8.03 ▼ $57.14	$2.21B	0.78	80,139 shs	119,709 shs
STOK Stoke Therapeutics	$31.40 -4.9%	$30.90	$18.00 ▼ $40.22	$2.03B	1.2	753,635 shs	1.10 million shs
ZBIO Zenas BioPharma	$31.62 +1.2%	$27.74	$13.50 ▼ $44.60	$2.06B	-1.03	846,710 shs	1.17 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KYTX Kyverna Therapeutics	+4.35%	+10.19%	+22.51%	-0.34%	+168.79%
NBTX Nanobiotix	+10.49%	+15.09%	+27.04%	+12.97%	+404.33%
STOK Stoke Therapeutics	+2.77%	+0.18%	+19.33%	+11.32%	+78.64%
ZBIO Zenas BioPharma	-2.07%	-0.13%	+1.79%	+57.51%	+97.16%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KYTX Kyverna Therapeutics	2.60	Moderate Buy	$30.00	269.00% Upside
NBTX Nanobiotix	2.50	Moderate Buy	$37.33	-14.53% Downside
STOK Stoke Therapeutics	2.73	Moderate Buy	$43.00	36.94% Upside
ZBIO Zenas BioPharma	2.56	Moderate Buy	$45.71	44.57% Upside

Current Analyst Ratings Breakdown

Latest KYTX, ZBIO, NBTX, and STOK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2026	ZBIO Zenas BioPharma	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$22.00 ➝ $32.00
8/14/2026	ZBIO Zenas BioPharma	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$55.00
8/14/2026	ZBIO Zenas BioPharma	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$45.00
8/7/2026	STOK Stoke Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
8/4/2026	STOK Stoke Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$60.00
8/4/2026	STOK Stoke Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$38.00 ➝ $40.00
8/4/2026	STOK Stoke Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$60.00 ➝ $58.00
8/4/2026	STOK Stoke Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$35.00
7/17/2026	NBTX Nanobiotix	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/13/2026	STOK Stoke Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$44.00
7/13/2026	STOK Stoke Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$44.00

(Data available from 8/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	$2.68 per share	N/A
NBTX Nanobiotix	$36.87M	59.97	N/A	N/A	($1.97) per share	-22.17
STOK Stoke Therapeutics	$184.42M	10.99	N/A	N/A	$5.36 per share	5.86
ZBIO Zenas BioPharma	$10M	206.10	N/A	N/A	$3.79 per share	8.34

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KYTX Kyverna Therapeutics	-$161.31M	-$2.94	N/A	N/A	N/A	N/A	-81.92%	-63.74%	N/A
NBTX Nanobiotix	-$27.11M	N/A	N/A	436.80	N/A	N/A	N/A	N/A	9/29/2026 (Estimated)
STOK Stoke Therapeutics	-$6.89M	-$3.34	N/A	N/A	N/A	-753.60%	-59.36%	-51.46%	11/3/2026 (Estimated)
ZBIO Zenas BioPharma	-$377.74M	-$8.99	N/A	N/A	N/A	N/A	-122.45%	-58.04%	N/A

Latest KYTX, ZBIO, NBTX, and STOK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	KYTX Kyverna Therapeutics	-$0.6783	-$0.63	+$0.0483	-$0.63	N/A	N/A
8/12/2026	Q2 2026	ZBIO Zenas BioPharma	-$1.12	-$1.77	-$0.65	-$1.77	$15.00 million	$1.00 million
8/3/2026	Q2 2026	STOK Stoke Therapeutics	-$0.7950	-$0.93	-$0.1350	-$0.93	$4.89 million	$9.33 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	N/A
NBTX Nanobiotix	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	N/A	N/A	N/A	N/A	N/A
ZBIO Zenas BioPharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KYTX Kyverna Therapeutics	0.15	9.06	9.06
NBTX Nanobiotix	N/A	1.09	1.09
STOK Stoke Therapeutics	N/A	7.69	7.69
ZBIO Zenas BioPharma	1.57	9.93	9.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KYTX Kyverna Therapeutics	18.08%
NBTX Nanobiotix	38.81%
STOK Stoke Therapeutics	N/A
ZBIO Zenas BioPharma	N/A

Insider Ownership

Company	Insider Ownership
KYTX Kyverna Therapeutics	17.60%
NBTX Nanobiotix	3.45%
STOK Stoke Therapeutics	9.60%
ZBIO Zenas BioPharma	22.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KYTX Kyverna Therapeutics	96	61.84 million	50.96 million	Optionable
NBTX Nanobiotix	100	50.62 million	48.87 million	Not Optionable
STOK Stoke Therapeutics	100	64.53 million	58.33 million	Optionable
ZBIO Zenas BioPharma	N/A	65.18 million	50.84 million	N/A

KYTX, ZBIO, NBTX, and STOK Headlines

Recent News About These Companies

HC Wainwright Forecasts Higher Earnings for Zenas BioPharma

August 20 at 1:29 AM | americanbankingnews.com

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 18 at 4:15 PM | globenewswire.com

HC Wainwright Predicts Higher Earnings for Zenas BioPharma

August 18 at 7:11 AM | marketbeat.com

Zenas BioPharma's (ZBIO) "Buy" Rating Reiterated at Guggenheim

August 17 at 1:18 AM | americanbankingnews.com

Zenas BioPharma's (ZBIO) "Outperform" Rating Reiterated at Wedbush

August 17 at 1:18 AM | americanbankingnews.com

Walleye Capital LLC Takes $5.31 Million Position in Zenas BioPharma, Inc. $ZBIO

August 15, 2026 | marketbeat.com

Zenas BioPharma's (ZBIO) Buy Rating Reaffirmed at Guggenheim

August 14, 2026 | marketbeat.com

Zenas BioPharma's (ZBIO) Outperform Rating Reiterated at Wedbush

August 14, 2026 | marketbeat.com

Zenas BioPharma (NASDAQ:ZBIO) Issues Earnings Results

August 13, 2026 | marketbeat.com

Zenas BioPharma (NASDAQ:ZBIO) Stock Price Down 6.6% on Disappointing Earnings

August 13, 2026 | marketbeat.com

Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 13, 2026 | globenewswire.com

Zenas BioPharma (ZBIO) Expected to Post Quarterly Earnings on Tuesday

August 9, 2026 | americanbankingnews.com

Zenas BioPharma (ZBIO) Projected to Release Quarterly Earnings on Tuesday

August 4, 2026 | marketbeat.com

Zenas BioPharma, Inc. (NASDAQ:ZBIO) Given Average Rating of "Moderate Buy" by Analysts

July 29, 2026 | marketbeat.com

Exome Asset Management LLC Takes Position in Zenas BioPharma, Inc. $ZBIO

July 28, 2026 | marketbeat.com

Zenas BioPharma (NASDAQ:ZBIO) Trading 7.7% Higher - Still a Buy?

July 27, 2026 | marketbeat.com

125,232 Shares in Zenas BioPharma, Inc. $ZBIO Bought by Walleye Capital LLC

July 24, 2026 | marketbeat.com

SEB Asset Management AB Invests $3.20 Million in Zenas BioPharma, Inc. $ZBIO

July 24, 2026 | marketbeat.com

Jennison Associates LLC Buys Shares of 250,000 Zenas BioPharma, Inc. $ZBIO

July 22, 2026 | marketbeat.com

Zenas BioPharma Grants Inducement Stock Options and RSUs to New Employees

July 17, 2026 | quiverquant.comQ

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 17, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYTX, ZBIO, NBTX, and STOK Company Descriptions

Kyverna Therapeutics NASDAQ:KYTX

$8.13 -0.74 (-8.34%)

As of 04:00 PM Eastern

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Nanobiotix NASDAQ:NBTX

$43.68 -1.71 (-3.77%)

Closing price 04:00 PM Eastern

Extended Trading

$43.50 -0.18 (-0.41%)

As of 04:21 PM Eastern

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

Stoke Therapeutics NASDAQ:STOK

$31.40 -1.63 (-4.93%)

Closing price 04:00 PM Eastern

Extended Trading

$31.30 -0.10 (-0.33%)

As of 04:21 PM Eastern

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Zenas BioPharma NASDAQ:ZBIO

$31.62 +0.37 (+1.18%)

Closing price 04:00 PM Eastern

Extended Trading

$31.63 +0.01 (+0.03%)

As of 04:27 PM Eastern

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KYTX, ZBIO, NBTX, and STOK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KYTX, ZBIO, NBTX, and STOK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KYTX, ZBIO, NBTX, and STOK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYTX, ZBIO, NBTX, and STOK Company Descriptions

Kyverna Therapeutics NASDAQ:KYTX

Nanobiotix NASDAQ:NBTX

Stoke Therapeutics NASDAQ:STOK

Zenas BioPharma NASDAQ:ZBIO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KYTX, ZBIO, NBTX, and STOK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KYTX, ZBIO, NBTX, and STOK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KYTX, ZBIO, NBTX, and STOK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYTX, ZBIO, NBTX, and STOK Company Descriptions

Kyverna Therapeutics NASDAQ:KYTX

Nanobiotix NASDAQ:NBTX

Stoke Therapeutics NASDAQ:STOK

Zenas BioPharma NASDAQ:ZBIO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools